Extended Data Fig. 3. Reductions in serum ANGPTL3, TG, LDL-C, VLDL-C, HDL-C, and non-HDL-C concentrations in healthy participants with single ascending doses of ARO-ANG3 or placebo.

Median percent change (+/-Q1,Q3) from baseline in triglycerides (B). Mean percent change (±SD) from baseline in ANGPTL3 (A), VLDL-C (C), non-HDL-C (D), LDL-C (E), HDL-C (F), and ApoB (G) in healthy participants receiving a subcutaneous dose of ARO-ANG3 (n = 4 per cohort of 35 mg [blue] 100 mg [red], 200 mg [green], 300 mg [purple]) or placebo [orange] on Day 1). Abbreviations: ApoB = Apolipoprotein B; HDL-C = high density lipoprotein cholesterol; Q1, Q3 = quartile 1, quartile 3; LDL-C = low density lipoprotein cholesterol; SD = standard deviation; VLDL = very low density cholesterol.